InterMune, Inc. (ITMN) said that it earned a $15 million development milestone under its development collaboration with Roche for the hepatitis C virus NS3 protease inhibitor compound ITMN-191, currently in a Phase 1b clinical trial in combination with Pegasys and Copegus.
As per the terms of collaboration agreement signed in October 2006, the clinical program for ITMN-191 is now being transitioned to Roche which, starting in Phase 2, will have primary responsibility for completing the global development and registration program.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.